AbbVie (NYSE:ABBV) said that when its ovarian cancer treatment Elahere launches in the UK, its list price will be the same as it is in the US.
The wholesale acquisition cost of Elahere (mirvetuximab soravtansine), which was approved in the UK in late July, is ~$6,487 per 100mL vial in the US.
“Developed markets must recognize and support the value that innovative therapies bring to patients and societies to help ensure sustainable access and continued investment in medical innovation so that patients everywhere benefit from the next generation of therapies,” EVP and Chief Commercial Jeff Stewart said in a statement.
The pharma added it is in talks with the National Institute for Health and Care Excellence (“NICE”), which is responsible for determining the cost-effectiveness of medicines in the UK, “to ensure that Elahere…is valued fairly. The value given to Elahere will determine the ability to launch in the U.K.”
AbbVie’s announcement Monday comes the same day that President Trump said that the prices of US drugs should be in-line with those paid by individuals in other countries under his “Most Favored Nation” policy.